Gland Pharma Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/f2dhadaxkja444ibdwmcqfb5.pdf

Key Takeaways


The Cenexi Acquisition: What It Adds and What It Costs Now

Srinivas Sadu: "The standalone margin of Gland probably is it's a long shot. It will take some time, but at least the margin improvement you should see from I think the target internally is 2 quarters from now, 1 to 2 quarters because the base costs are higher compared to here."

US Business: Rebuilding After Customer Exits

Srinivas Sadu: "So, kind of price erosion kind of it's neutral. If you look at our growth coming from quarter-on-quarter, the growth came from new launches, about 10%, 11% and volume growth about 4%, 5%. But from prices, it's almost stable. I think 1% negative or something."

Complex Injectables Pipeline: Building the Next Margin Tier


Rest-of-World and Other Markets: Pruning for Profitability

Srinivas Sadu: "Some of the products where it's very low margin, especially the Enoxa and Heparin. Because it's a low-margin business, it's time to focus on the high margin. Now that the revenue we have high revenue coming from Cenexi business also, I think it's time for us to increase profitability."

Competitive Landscape and Pricing Discipline

Srinivas Sadu: "There is an aggressive pricing, which happened, I would say, still recent past. We see now a bit reasonable in terms of the launches what we have made in the recently. So I think people are realizing long-term it doesn't work with that kind of an aggressive pricing, especially with the FDA inspections happening and going after aggressively the facilities."

Guidance & Commitments

CommitmentSpecificsTimeline
US sequential growthSteady QoQ growth, no decrease expectedOngoing from Q1 FY24
Enoxaparin US recoveryShipments to resume under active Kabi agreement; Kabi expects ~1.5 crore syringes/yearFrom Q2 FY24
Relaunches from exited customer portfolio12–13 products to launchQ2 FY24
Cenexi summer shutdown impactUp to 4 weeks shutdown; Q2 revenue expected in similar range as the 2-month Q1 consolidationQ2 FY24
Cenexi margin improvementImprovement visible as base costs are higher; internal target 1–2 quarters outQ3–Q4 FY24
China product launches4 products expected to launchNext 9–12 months
Complex injectable approvalsFirst set of approvals expectedQ4 FY24 or Q1 FY25
Complex injectable filings4 more filings this year (total 11), 8 more in next 12–14 months (total 19)FY24 and FY25
Cenexi annual revenueLast year ~EUR 190 million; assume similar range this yearFY24

Key Metrics

MetricQ1 FY24
Revenue from operations₹1,208.7 cr, +41% YoY (37% from Cenexi consolidation, 4% base business growth)
Gross margin63%, up from 56% in Q1 FY23
EBITDA₹298.2 cr, +10% YoY
EBITDA margin25% consolidated; base business maintained 30%
Net profit₹194.1 cr, -15% YoY
PAT margin16%
Effective tax rate25.7%
R&D expense₹45.7 cr, 5% of revenue from operations
Base business revenue growth4% YoY
U.S. market revenue growth23% QoQ, -8% YoY
Rest of World revenue growth62% YoY, 18% of Q1 FY24 revenue
India market revenue growth27% YoY, 7% of Q1 FY24 revenue
Profit share and milestone income11% of standalone revenue
Cash flow from operations₹62.9 cr for the first 3 months
Cash conversion cycle233 days
Net cash position₹1,635.6 cr as of June 30, 2023
ANDA filings337 total filings, 270 approved, 67 pending as of June 30, 2023
U.S. product launches in Q123 molecules launched
Cenexi revenue (2 months)₹321.4 cr, gross margin of 76%, EBITDA of ₹34.7 cr